Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo
Status:
Completed
Trial end date:
2020-02-04
Target enrollment:
Participant gender:
Summary
Patients with partial seizures currently taking 1-3 antiepileptic medications will have a
50:50 chance to receive Lyrica 300 mg per day or placebo (no active ingredients) added on to
their current medications for 3 months. Neither the study doctor nor the patient will know
the medication assignment. Vision testing will be performed prior to receiving the study
treatment and at the end of the study to see if there are any changes.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.